Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA
09 avr. 2019 21h00 HE
|
Innovative Cellular Therapeutics
SHANGHAI, China and ROCKVILLE, Md., April 09, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of...
Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA
19 mars 2019 08h00 HE
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced it...
Pet Cancer Therapeutics Market to hit $359.4 Million by 2025: Global Market Insights, Inc.
15 mars 2019 03h04 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, March 15, 2019 (GLOBE NEWSWIRE) -- Australian pet cancer therapeutics market is forecast to grow at over 12.6% CAGR in given timeframe. High growth is due to growing...
Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members to Executive Leadership Team
06 mars 2019 17h00 HE
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 06, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced...
Ett nytt studieresultat med AroCell TK 210 ELISA vid prostatacancer har accepterats för publicering
25 févr. 2019 02h30 HE
|
AroCell AB
Studien med titeln “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions”,...
New study results with AroCell TK 210 ELISA in prostate cancer has been accepted for publication
25 févr. 2019 02h30 HE
|
AroCell AB
The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous...
Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
07 févr. 2019 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Viracta Announces Scientific Advisory Board Formation
25 sept. 2018 08h00 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other...
New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
24 août 2018 07h50 HE
|
AroCell AB
A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...
Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma
13 août 2018 11h15 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the activation of a second clinical...